Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis.

ABSTRACT:

Background

Elderly patients tend to be underrepresented in renal cell carcinoma (RCC) clinical trials. The Sorafenib RCC Integrated Database includes data from six clinical trials and two expanded-access studies evaluating sorafenib monotherapy in >4600 patients with RCC. Using this database, sorafenib tolerability and treatment patterns were analysed according to age group (<55, 55-<65, 65-<75, or ≥ 75 years).

Methods

Dosing patterns, and incidence, prevalence and cumulative incidence of drug-related adverse events (DRAEs) and fatal DRAEs were assessed.

Results

Overall, 4684 patients were evaluable (<55 years, n=1126; 55-<65, n=1579; 65-<75, n=1382; ≥ 75, n=559). Treatment patterns were generally similar across subgroups, although sorafenib treatment duration was ∼30

SUBMITTER: Procopio G 

PROVIDER: S-EPMC3566810 | biostudies-literature | 2013 Feb

REPOSITORIES: biostudies-literature